List of Contents

Cancer Gene Therapy Market Size, Share, and Trends 2024 to 2033

Cancer Gene Therapy Market (By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer; By End-User: Hospitals, Biopharmaceutical Companies, Diagnostic centers, Research Institutes, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : April 2024
  • Report Code : 2893
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Gene Therapy Market 

5.1. COVID-19 Landscape: Cancer Gene Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Gene Therapy Market, By Therapy

8.1. Cancer Gene Therapy Market, by Therapy, 2024-2033

8.1.1. Gene Induced Immunotherapy

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Oncolytic Virotherapy

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Gene Transfer

8.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Cancer Gene Therapy Market, By End-User

9.1. Cancer Gene Therapy Market, by End-User, 2024-2033

9.1.1. Hospitals

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Biopharmaceutical Companies

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Diagnostic centers

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Research Institutes

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Cancer Gene Therapy Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.1.2. Market Revenue and Forecast, by End-User (2021-2033)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.1.3.2. Market Revenue and Forecast, by End-User (2021-2033)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.1.4.2. Market Revenue and Forecast, by End-User (2021-2033)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.2.2. Market Revenue and Forecast, by End-User (2021-2033)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.2.3.2. Market Revenue and Forecast, by End-User (2021-2033)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.2.4.2. Market Revenue and Forecast, by End-User (2021-2033)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.2.5.2. Market Revenue and Forecast, by End-User (2021-2033)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.2.6.2. Market Revenue and Forecast, by End-User (2021-2033)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.3.2. Market Revenue and Forecast, by End-User (2021-2033)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.3.3.2. Market Revenue and Forecast, by End-User (2021-2033)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.3.4.2. Market Revenue and Forecast, by End-User (2021-2033)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.3.5.2. Market Revenue and Forecast, by End-User (2021-2033)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.3.6.2. Market Revenue and Forecast, by End-User (2021-2033)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.4.2. Market Revenue and Forecast, by End-User (2021-2033)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.4.3.2. Market Revenue and Forecast, by End-User (2021-2033)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.4.4.2. Market Revenue and Forecast, by End-User (2021-2033)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.4.5.2. Market Revenue and Forecast, by End-User (2021-2033)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.4.6.2. Market Revenue and Forecast, by End-User (2021-2033)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.5.2. Market Revenue and Forecast, by End-User (2021-2033)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.5.3.2. Market Revenue and Forecast, by End-User (2021-2033)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Therapy (2021-2033)

10.5.4.2. Market Revenue and Forecast, by End-User (2021-2033)

Chapter 11. Company Profiles

11.1. OncoGenex Pharmaceuticals Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. MerckKGaA

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Introgen TherapeuticsInc

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. GSK plc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. GenVec

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Genelux Corporation

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Elevate BioInc

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. CelgeneInc

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Bluebird bio Inc.

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. BioCancell Inc.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client